Showing 721 - 740 results of 100,532 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( 5 ((mg decrease) OR (a decrease)) ))', query time: 1.35s Refine Results
  1. 721
  2. 722

    Preconditioning anti-VEGF antibody decreased IR-induced pulmonary edema and microvascular hyper-permeability. by Chou-Chin Lan (2938674)

    Published 2016
    “…The Kf2 was significantly increased in the IR group and decreased in the B5-IR group (5 mg/kg) (p<0.05). There was a significant difference from the * CTRL (<i>p</i><0.05) and <sup>#</sup>IR (<i>p</i><0.05) groups. …”
  3. 723
  4. 724
  5. 725

    Preconditioning anti-VEGF antibody decreased total protein concentration and pro-inflammatory cytokines in BALF. by Chou-Chin Lan (2938674)

    Published 2016
    “…Preconditioning anti-VEGF antibody (5 mg/kg) decreased IR-induced total protein concentration and TNF-α in BALF (both <i>p</i><0.05). …”
  6. 726
  7. 727

    Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

    Published 2024
    “…Colors indicate samples from different animals. Large circles show mean of cells from 5 fields of view from a single animal. …”
  8. 728
  9. 729
  10. 730
  11. 731
  12. 732
  13. 733
  14. 734
  15. 735
  16. 736
  17. 737

    LPS-induced decrease in Sp1 DNA binding activity is associated with an increased NF-κB binding activity. by Xiaobing Ye (49295)

    Published 2015
    “…(A) and (C): EMSA photographs show that LPS-induced decrease in Sp1 DNA binding activity is associated with an increased NF-κB binding activity.…”
  18. 738

    Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  19. 739
  20. 740